Wednesday, August 7, 2013
Ocular Surgery News
Following positive 1-year outcomes from two phase 3 trials of aflibercept as a treatment for diabetic macular edema, Regeneron Pharmaceuticals announced it plans to submit an application for U.S. marketing approval this year, approximately 1 year ahead of the previous timeline, according to a company news release.